Language: BG BG
nav.cta
← Back to results
Recruiting Phase 3 NCT07241390

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Phase 3 – large-scale trial before approval
Conditions: Atherosclerosis Cardiovascular Disease Chronic Kidney Disease

Sponsor: Eli Lilly and Company

trial.available_in: БГ
Overview
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Who can participate
Inclusion Criteria: * Have established ASCVD and/or CKD Exclusion Criteria: * Have type 1 diabetes * Have had a major heart condition within 60 days prior to screening * Have New York Heart Association Functional Classification Class IV heart failure
Locations 36
Argentina (1)
Instituto de Investigaciones Clínicas Bahia Blanca
Bahía Blanca
Australia (1)
Nightingale Research
Adelaide
Belgium (1)
Imelda General Hospital
Bonheiden
NOT_YET_RECRUITING
Brazil (1)
Centro de Pesquisa Clinica do Coracao
Aracaju
NOT_YET_RECRUITING
Bulgaria (1)
Medical Center New Polyclinic Gabrovo
Gabrovo
NOT_YET_RECRUITING
Canada (1)
Centricity Research Brampton Endocrinology
Brampton
China (1)
Peking University People's Hospital
Beijing
Colombia (1)
Fundacion Cardiomet Cequin
Armenia
NOT_YET_RECRUITING
Czech Republic (1)
Diacentrum Brandys n.L. s.r.o.
Brandýs nad Labem
NOT_YET_RECRUITING
Estonia (1)
Private Practice - Dr. Liina Viitas
Pärnu
NOT_YET_RECRUITING
France (1)
Centre Hospitalier Universitaire - Hôpitaux de Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume
NOT_YET_RECRUITING
Germany (1)
Zentrum fur klinische Forschung - Köln
Cologne
NOT_YET_RECRUITING
Greece (1)
Athens Medical Center - Psychikon branch
Athens
NOT_YET_RECRUITING
Hungary (1)
DRC Gyógyszervizsgáló Központ
Balatonfüred
NOT_YET_RECRUITING
India (1)
Gujarat Endocrin Pvt Ltd
Ahmedabad
NOT_YET_RECRUITING
Israel (1)
Assuta Ashdod Medical Center
Ashdod
Italy (1)
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna
NOT_YET_RECRUITING
Japan (1)
Tokyo-Eki Center-building Clinic
Chūōku
Lithuania (1)
Viešoji Istaiga Alytaus Poliklinika
Alytus
NOT_YET_RECRUITING
Malaysia (1)
Hospital Raja Permaisuri Bainun Ipoh
Ipoh
NOT_YET_RECRUITING
Mexico (1)
Centro de Atencion al Diabetico Actopan
Actopan
NOT_YET_RECRUITING
Netherlands (1)
Jeroen Bosch Hospital
's-Hertogenbosch
NOT_YET_RECRUITING
New Zealand (1)
Aotearoa Clinical Trials
Auckland
NOT_YET_RECRUITING
Philippines (1)
Baguio General Hospital
Baguio City
NOT_YET_RECRUITING
Poland (1)
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok
NOT_YET_RECRUITING
Romania (1)
CMI Cardiologie - Dr. Mercea Corina Delia
Baia Mare
NOT_YET_RECRUITING
Serbia (1)
Clinical Center of Serbia
Belgrade
NOT_YET_RECRUITING
Slovakia (1)
Diacrin s.r.o.
Bratislava
NOT_YET_RECRUITING
South Africa (1)
TREAD Research
Cape Town
NOT_YET_RECRUITING
South Korea (1)
The Catholic University of Korea, Bucheon St. Mary's Hospital
Bucheon-si
Spain (1)
Centro Periférico de Especialidades Bola Azul
Almería
NOT_YET_RECRUITING
Taiwan (1)
Changhua Christian Hospital
Changhua County
NOT_YET_RECRUITING
Thailand (1)
Faculty of Medicine Siriraj Hospital
Bangkok
NOT_YET_RECRUITING
Tunisia (1)
Hopital Regional Mohamed Tahar Al Maamouri
Nabeul
NOT_YET_RECRUITING
Ukraine (1)
Regional Communal Non-commercial enterprise "Chernivtsi regional clinical hospital"
Chernivtsi
United Kingdom (1)
FutureMeds - Birmingham
Birmingham
Technical details
Status
Recruiting
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
50 Years
Healthy volunteers
No
Start date
01.12.2025
Completion date
01.08.2031
Registry ID
NCT07241390
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.